Financials Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:12:20 18/07/2024 pm IST 5-day change 1st Jan Change
47.67 USD -0.60% Intraday chart for Ionis Pharmaceuticals, Inc. +0.43% -6.08%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 8,497 7,906 4,297 5,365 7,258 6,995 - -
Enterprise Value (EV) 1 8,602 8,047 4,649 4,561 6,157 6,799 7,259 7,412
P/E ratio 29 x -17.5 x -152 x -19.9 x -19.8 x -12.7 x -14.6 x -27.1 x
Yield - - - - - - - -
Capitalization / Revenue 7.57 x 10.8 x 5.3 x 9.14 x 9.21 x 11.7 x 9.13 x 6.44 x
EV / Revenue 7.66 x 11 x 5.74 x 7.77 x 7.81 x 11.3 x 9.48 x 6.83 x
EV / EBITDA 22.7 x -50.7 x 35.6 x -11.5 x -18 x -12.3 x -12.9 x -28 x
EV / FCF 27.3 x 10.4 x 247 x -15.7 x -18.6 x -13.1 x -13.1 x -20.3 x
FCF Yield 3.66% 9.59% 0.41% -6.36% -5.38% -7.63% -7.62% -4.93%
Price to Book 5.12 x 9.39 x 5.57 x 9.37 x 18.9 x -121 x -16.4 x -12.3 x
Nbr of stocks (in thousands) 1,40,663 1,39,823 1,41,210 1,42,050 1,43,472 1,45,846 - -
Reference price 2 60.41 56.54 30.43 37.77 50.59 47.96 47.96 47.96
Announcement Date 26/02/20 24/02/21 24/02/22 22/02/23 21/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,123 729 810 587 788 599.4 766.1 1,086
EBITDA 1 378.4 -158.7 130.5 -395.9 -342.7 -551.8 -562.4 -264.9
EBIT 1 366 -172 -30 -411 -353 -569.9 -484.8 -288.7
Operating Margin 32.59% -23.59% -3.7% -70.02% -44.8% -95.07% -63.28% -26.59%
Earnings before Tax (EBT) 1 347 -170 -30 -258 -334 -575.8 -530.7 -334.4
Net income 1 294 -451 -29 -270 -366 -569.2 -516.2 -294.5
Net margin 26.18% -61.87% -3.58% -46% -46.45% -94.95% -67.38% -27.13%
EPS 2 2.080 -3.230 -0.2000 -1.900 -2.560 -3.789 -3.289 -1.773
Free Cash Flow 1 314.8 772 18.84 -290.1 -331.3 -518.7 -553.5 -365.5
FCF margin 28.03% 105.9% 2.33% -49.42% -42.05% -86.53% -72.25% -33.66%
FCF Conversion (EBITDA) 83.19% - 14.44% - - - - -
FCF Conversion (Net income) 107.08% - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 26/02/20 24/02/21 24/02/22 22/02/23 21/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 440 142 134 160 152 131 188 144 325 119 146.5 157.4 176.5 137.5 186.2
EBITDA 1 247.8 -53.8 -81.73 -55.34 -205 -111.4 - -140.7 -3.456 -147 -142.1 -128 -119.3 - -
EBIT 1 221 -57 -86 -59 -208 -114 -91 -143 -6 -150 -146.2 -147.2 -140.5 -176.6 -137
Operating Margin 50.23% -40.14% -64.18% -36.88% -136.84% -87.02% -48.4% -99.31% -1.85% -126.05% -99.79% -93.51% -79.58% -128.39% -73.59%
Earnings before Tax (EBT) 1 225 -64 -103 -47 -44 -113 -77 -141 -3 -143 -145.7 -145.7 -144.3 -204.1 -164.2
Net income 1 225 -65 -105 -47 -52 -124 -85 -147 -9 -143 -142.1 -144.7 -141.5 -204.8 -164.8
Net margin 51.14% -45.77% -78.36% -29.38% -34.21% -94.66% -45.21% -102.08% -2.77% -120.17% -97% -91.92% -80.13% -148.92% -88.55%
EPS 2 1.410 -0.4600 -0.7400 -0.3300 -0.3700 -0.8700 -0.6000 -1.030 -0.0600 -0.9800 -0.9334 -0.9549 -0.9091 -1.284 -1.088
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 24/02/22 04/05/22 09/08/22 09/11/22 22/02/23 03/05/23 09/08/23 02/11/23 21/02/24 07/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 104 141 352 - - - 264 417
Net Cash position 1 - - - 804 1,102 196 - -
Leverage (Debt/EBITDA) 0.2755 x -0.8912 x 2.697 x - - - -0.4695 x -1.574 x
Free Cash Flow 1 315 772 18.8 -290 -331 -519 -553 -365
ROE (net income / shareholders' equity) 23.4% -3.88% -3.78% -40.1% -76.3% -271% -568% -528%
ROA (Net income/ Total Assets) 9.97% -4.4% -1.14% -10.5% -13.3% -22.6% -25.4% -6.74%
Assets 1 2,949 10,245 2,536 2,575 2,760 2,520 2,036 4,367
Book Value Per Share 2 11.80 6.020 5.470 4.030 2.680 -0.4000 -2.930 -3.890
Cash Flow per Share 2 2.420 0.2600 0.2200 -1.930 -2.150 -3.060 -3.420 -
Capex 1 30.9 35.1 12 15.7 23.8 22.5 24.6 29
Capex / Sales 2.75% 4.82% 1.48% 2.68% 3.02% 3.76% 3.21% 2.67%
Announcement Date 26/02/20 24/02/21 24/02/22 22/02/23 21/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
47.96 USD
Average target price
59.39 USD
Spread / Average Target
+23.83%
Consensus
  1. Stock Market
  2. Equities
  3. IONS Stock
  4. Financials Ionis Pharmaceuticals, Inc.